Integrity Applications, Inc. Enters Into Manufacturing Agreement With Wistron Corp.

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp.

ASHKELON, Israel, July 21, 2014 /PRNewswire/ -- Integrity Applications, Inc. (OTCQB: IGAP) (the “Company” or “Integrity”), developer of the GlucoTrack® model DF-F noninvasive blood glucose measurement device, announced today that it has entered, through its wholly-owned subsidiary, Integrity Applications Ltd., into a Manufacturing Agreement with Wistron Corp, the manufacturing arm of Acer Inc. Pursuant to the agreement, Wistron has agreed to manufacture and service (on a non-exclusive basis) the GlucoTrack Model DF-F and any future products, if any, introduced by the Company. Wistron has agreed to provide full turn-key manufacturing services for the GlucoTrack model DF-F, including components procurement, units assembly, device integration, testing and packaging.

Integrity Applications Logo

About GlucoTrack

GlucoTrack features a small sensor that clips to the earlobe and measures the wearer’s blood glucose level by taking measurements using three technologies. The measurements are analyzed using a proprietary algorithm and displayed on a small handheld device, the size of a mobile phone. The derived blood glucose measurement is also announced verbally, making it suitable for the elderly and vision-impaired diabetes patients. The Company has obtained a CE Mark approval for its GlucoTrack Model DF-F in Europe (June 2013) and intends to seek Food and Drug Administration approval for GlucoTrack Model DF-F in the United States.

About Integrity Applications, Inc.

Integrity Applications, Inc. is a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. Integrity Applications has developed the GlucoTrack model DF-F non-invasive glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level measurements without the pain, inconvenience, incremental cost and difficulty or discomfort of conventional (invasive) spot finger stick devices. Integrity Applications operates primarily through its wholly-owned Israeli subsidiary, A.D. Integrity Applications, Ltd. For more information please visit www.integrity-app.com.

About Wistron Corporation

Wistron Corporation (TSE: 3231.TW) is an ODM (original design manufacturer) providing a variety of support services related to design, manufacturing, and after-sales services for Information and Communication Technology (ICT) products, including PCs, Smartphones, Tablets, Server and Storage systems, Industrial PCs, Medical and Healthcare products, LCD TVs and Digital Home products, etc. Wistron sells products to clients who use their own brands to introduce the products into the marketplace. The full array of R&D and engineering teams allows Wistron’s customers to outsource some or all of their product development tasks. In-house expertise allows customers to quickly move ahead with their marketing and product introduction plans by relying on Wistron to manage product development, parts procurement, manufacturing, and customer service processes and activities.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “expect,” and “will,” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications’ results include, but are not limited to, the ability of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); the ability of Integrity Applications to successfully commercialize the GlucoTrack model DF-F; the ability of the GlucoTrack model DF-F to achieve acceptable pricing, adequate third party reimbursement or market acceptance; the ability of Integrity Applications to manage its growth and the expansion of its operations to include commercialization activities; risks relating to the use of third party manufacturers; risks relating to the development of Integrity Applications’ sales, marketing and distribution capability, either on its own or through collaborations with marketing partners; and the additional risk factors described in Integrity Applications’ filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2013.

Contact:

Eran Hertz, CFO
Integrity Applications
+972 (8) 675-7878 ext. #3
eranh@integrity-app.com

Logo - http://photos.prnewswire.com/prnh/20140702/124015

SOURCE Integrity Applications, Inc.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC